Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLA-1 + cisplatin
- Development stage
- Preclinical
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
PLA-1 + cisplatin is an experimental nanoparticle-based drug delivery system designed for the treatment of hepatocellular carcinoma (HCC). It consists of a metal-organic framework (MOF), designated as "1", synthesized from an organic ligand (L) coordinated with copper (Cu(II)) and iodine (I(I)), which is then incorporated with polylactic acid (PLA) to form a composite carrier (PLA-1). This carrier is loaded with cisplatin, a platinum-based chemotherapeutic agent. The system is designed to provide controlled, sustained release of cisplatin, thereby enhancing its efficacy and reducing systemic side effects. In preclinical studies using HepG-2 and Huh-7 cell lines, the formulation demonstrated dose-dependent cytotoxicity, significantly upregulating the expression of the tumor suppressor GADD45A and downregulating the oncogene NACC1.
- Other names
- PLA-1-cisplatinPLA1-cisplatinPLA 1-cisplatincisplatin-loaded PLA-MOF nanoparticle
02
Targets
DNAGSTP1 (Glutathione S-transferase P)P4HB (Protein disulfide-isomerase)VIM (Vimentin)GADD45A (Growth arrest and DNA-damage-inducible protein GADD45 alpha)NACC1 (Nucleus accumbens-associated protein 1)
Beyond the preview
Go deeper on PLA-1 + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLA-1 + cisplatin.